Molecular mechanisms of proteinuria in diabetes

Biochemical Society Transactions

Volumn 36, Issue 5, 2008, Pages 946-949

  Gnudi, Luigi ^a  

^a Unit for Metabolic Medicine   (United Kingdom)

Author keywords

Albuminuria; Blood pressure; Diabetes; Kidney disease; Proteinuria; Transforming growth factor 1 (TGF 1); Vascular endothelial growth factor (VEGF)

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANGIOTENSIN 1 RECEPTOR; GLUCOSE TRANSPORTER 1; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

CELL ACTIVATION; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENETIC LINKAGE; GLOMERULUS EPITHELIUM; GLOMERULUS FILTRATION; GLUCOSE TRANSPORT; HEMODYNAMIC PARAMETERS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; UPREGULATION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; EXCITATORY AMINO ACID TRANSPORTER 2; HEMODYNAMICS; HUMANS; KIDNEY GLOMERULUS; PROTEINURIA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 53849127166     PISSN: 03005127     EISSN: None     Source Type: Journal    
DOI: 10.1042/BST0360946     Document Type: Conference Paper

References (68)

1. Cooper, M.E. (2001) Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44, 1957-1972
2. Gnudi, L., Thomas, S.M. and Viberti, G. (2007) Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. J. Am. Soc. Nephrol. 18, 2226-2232
3. Jamerson, K.A. (2005) Preventing chronic kidney disease in special populations. Am. J. Hypertens. 18, 106S-111S
4. Deckert, T., Feldt-Rasmussen, B., Borch-Johnsen, K., Jensen, T. and Kofoed-Enevoldsen, A. (1989) Albuminuria reflects widespread vascular damage: the STENO hypothesis. Diabetologia 32, 219-226
5. De Zeeuw, D. (2004) Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int. 66, (Suppl. 92), S2-S6
6. Ruggenenti, P., Schieppati, A. and Remuzzi, G. (2001) Progression, remission, regression of chronic renal diseases. Lancet 357, 1601-1608
7. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986
8. Adler, A.I., Stratton, I.M., Neil, H.A., Yudkin, J.S., Matthews, D.R., Cull, C.A., Wright, A.D., Turner, R.C. and Holman, R.R. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br. Med. J. 321, 412-419
9. Hostetter, T.H. (1994) Mechanisms of diabetic nephropathy. Am. J. Kidney Dis. 23, 188-192
10. Stratton, I.M., Adler, A.I., Neil, H.A., Matthews, D.R., Manley, S.E., Cull, C.A., Hadden, D., Turner, R.C. and Holman, R.R. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. 321, 405-412
11. Lewis, J.B., Berl, T., Bain, R.P., Rohde, R.D. and Lewis, E.J. (1999) Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am. J. Kidney Dis. 34, 809-817
12. Hostetter, T.H., Troy, J.L. and Brenner, B.M. (1981) Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int. 19, 410-415
13. Hostetter, T.H., Rennke, H.G. and Brenner, B.M. (1982) The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am. J. Med. 72, 375-380
14. Ito, S. and Abe, K. (1997) Contractile properties of afferent and efferent arterioles. Clin. Exp. Pharmacol. Physiol. 24, 532-535
15. De Vriese, A.S., Stoenoiu, M.S., Elger, M., Devuyst, O., Vanholder, R., Kriz, W. and Lameire, N.H. (2001) Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide. Kidney Int. 60, 202-210
16. Kagami, S., Border, W.A., Miller, D.E. and Noble, N.A. (1994) Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J. Clin. Invest. 93, 2431-2437
17. Raij, L. (2005) The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease. Am. J. Hypertens. 18, 95S-99S
18. Sharma, K., Cook, A., Smith, M., Valancius, C. and Inscho, E.W. (2005) TGF-β impairs renal autoregulation via generation of ROS. Am. J. Physiol. Renal Physiol. 288, F1069-F1077
19. Anderson, S. and Vora, J.P. (1995) Current concepts of renal hemodynamics in diabetes. J. Diabetes Complications 9, 304-307
20. Maddox, D.A. and Brenner, B.M. (2000) Glomerular ultrafiltration in The Kidney (Brenner, B.M. and Rector, Jr, F.C., eds), pp. 319-374, W.B. Saunders and Co., Philadelphia
21. Arima, S. and Ito, S. (2003) The mechanisms underlying altered vascular resistance of glomerular afferent and efferent arterioles in diabetic nephropathy. Nephrol. Dial. Transplant. 18, 1966-1969
22. Ziyadeh, F.N. (2004) Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J. Am. Soc. Nephrol. 15, (Suppl. 1), S55-S57
23. Wang, L., Kwak, J.H., Kim, S.I., He, Y. and Choi, M.E. (2004) TGF-β1 stimulates vascular endothelial growth factor (VEGF) 164 via mitogen-activated protein kinase kinase 3 (MKK3)-p38α and p38δ MAPK dependent pathway in murine mesangial cells. J. Biol. Chem. 279, 33213-33219
24. Riser, B.L. and Cortes, P. (2001) Connective tissue growth factor and its regulation: a new element in diabetic glomerulosclerosis. Renal Failure 23, 459-470
25. Amemiya, T., Sasamura, H., Mifune, M., Kitamura, Y., Hirahashi, J., Hayashi, M. and Saruta, T. (1999) Vascular endothelial growth factor activates MAP kinase and enhances collagen synthesis in human mesangial cells. Kidney Int. 56, 2055-2063
26. Chen, S., Kasama, Y., Lee, J.S., Jim, B., Marin, M. and Ziyadeh, F.N. (2004) Podocyte-derived vascular endothelial growth factor mediates the stimulation of α3(IV) collagen production by transforming growth factor-β1 in mouse podocytes. Diabetes 53, 2939-2949
27. Azar, S., Limas, C., Iway, J. and Weller, D. (1979) Single nephron dynamics during high sodium intake and early hypertension in Dahl rats. Jpn. Heart J. 20, (Suppl. 1), 138-140
28. Takenaka, T., Forster, H., De Micheli, A. and Epstein, M. (1992) Impaired myogenic responsiveness of renal microvessels in Dahl salt-sensitive rats. Circ. Res. 71, 471-480
29. Faraj, A.H. and Morley, A.R. (1992) Remnant kidney pathology after five-sixth nephrectomy in rat. I. A biochemical and morphological study. APMIS 100, 1097-1105
30. Hayakawa, H. and Raij, L. (1998) Nitric oxide synthase activity and renal injury in genetic hypertension. Hypertension 31, 266-270
31. Arendshorst, W.J. (1979) Autoregulation of renal blood flow in spontaneously hypertensive rats. Circ. Res. 44, 344-349
32. Raij, L., Azar, S. and Keane, W.F. (1985) Role of hypertension in progressive glomerular immune injury. Hypertension 7, 398-404
33. Inoki, K., Haneda, M., Maeda, S., Koya, D. and Kikkawa, R. (1999) TGF-β1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells. Kidney Int. 55, 1704-1712
34. Gnudi, L., Viberti, G., Raij, L., Rodriguez, V., Burt, D., Cortes, P., Hartley, B., Thomas, S., Maestrini, S. and Gruden, G. (2003) GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension 42, 19-24
35. Zhang, J., Liu, Z., Liu, H., Li, Y. and Li, L. (2000) Regulation of the expression and function of glucose transporter-1 by TGF-β1 and high glucose in mesangial cells. Chin. Med. J. (Engl.) 113, 508-513
36. Nose, A., Mori, Y., Uchiyama-Tanaka, Y., Kishimoto, N., Maruyama, K., Matsubara, H. and Iwasaka, T. (2003) Regulation of glucose transporter (GLUT1) gene expression by angiotensin II in mesangial cells: involvement of HB-EGF and EGF receptor transactivation. Hypertens. Res. 26, 67-73
37. Heilig, C.W., Concepcion, L.A., Riser, B.L., Freytag, S.O., Zhu, M. and Cortes, P. (1995) Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J. Clin. Invest. 96, 1802-1814
38. Heilig, C.W., Kreisberg, J.I., Freytag, S., Murakami, T., Elbina, Y., Guo, L., Heilig, K., Loberg, R., Qu, X., Jin, Y. et al. (2001) Antisense GLUT-1 protects mesangial cells from glucose induction of GLUT-1 and fibronectin expression. Am. J. Physiol. Renal Physiol. 280, F657-F666
39. Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820
40. King, G.L., Kunisaki, M., Nishio, Y., Inoguchi, T., Shiba, T. and Xia, P. (1996) Biochemical and molecular mechanisms in the development of diabetic vascular complications. Diabetes 45, (Suppl. 3), S105-S108
41. Kolm-Litty, V., Sauer, U., Nerlich, A., Lehmann, R. and Schleicher, E.D. (1998) High glucose induced transforming growth factor β1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cell. J. Clin. Invest. 101, 160-169
42. Adhikary, L., Chow, F., Nikolic-Paterson, D.J., Stambe, C., Dowling, J., Atkins, R.C. and Tesch, G.H. (2004) Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy Diabetologia 47, 1210-1222
43. Burt, D.J., Gruden, G., Thomas, S.M., Tutt, P., Dell'Anna, C., Viberti, G.C. and Gnudi, L. (2003) p38 mitogen-activated protein kinase mediates hexosamine-induced TGFβ1 mRNA expression in human mesangial cells. Diabetologia 46, 531-537
44. Gruden, G., Zonca, S., Hayward, A., Thomas, S., Maestrini, S., Gnudi, L. and Viberti, G.C. (2000) Mechanical stretch-induced fibronectin and transforming growth factor-β1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent. Diabetes 49, 655-661
45. Igarashi, M., Wakasaki, H., Takahara, N., Ishii, H., Jiang, Z.Y., Yamauchi, T., Kuboki, K., Meier, M., Rhodes, C.J. and King, G.L. (1999) Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J. Clin. Invest. 103, 185-195
46. Koya, D. and King, G.L. (1998) Protein kinase C activation and the development of diabetic complications. Diabetes 47, 359-866
47. Henry, D.N., Busik, J.V., Brosius, III, F.C. and Heilig, C.W. (1999) Glucose transporters control gene expression of aldose reductase, PKCα, and GLUT1 in mesangial cells in vitro. Am. J. Physiol. 277, F97-F104
48. Becker, B.N., Yasuda, T., Kondo, S., Vaikunth, S., Homma, T. and Harris, R.C. (1998) mechanical stretch/relaxation stimulates a cellular rennin-angiotensin system in cultured rat mesangial cells. Exp. Nephrol. 6, 57-66
49. Weigert, C., Brodbeck, K., Klopfer, K., Haring, H.U. and Schleicher, E.D. (2002) Angiotensin II induces human TGF-β1 promoter activation: similarity to hyperglycaemia. Diabetologia 45, 890-898
50. D'Agord, S.B., Lacchini, S., Bertoluci, M.C., Irigoyen, M.C., Machado, U.F. and Schmid, H. (2001) Increased renal GLUT1 abundance and urinary TGF-β1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes. Horm. Metab. Res. 33, 664-669
51. D'Agord, S.B., Lacchini, S., Bertoluci, M.C., Irigoyen, M.C., Machado, U.F. and Schmid, H. (2003) Impact of renal denervation on renal content of GLUT1, albuminuria and urinary TGF-β1 in streptozotocin-induced diabetic rats. Auton. Neurosci. 104, 88-94
52. Daniels, M.C., Kansal, P., Smith, T.M., Paterson, A.J., Kudlow, J.E. and McClain, D.A. (1993) Glucose regulation of transforming growth factor-α expression is mediated by products of the hexosamine biosynthesis pathway. Mol. Endocrinol. 7, 1041-1048
53. Cao, Z., Cooper, M.E., Wu, L.L., Cox, A.J., Jandeleit-Dahm, K., Kelly, D.J. and Gilbert, R.E. (2000) Blockade of the rennin-angiotensin and endothelin systems on progressive renal injury. Hypertension 36, 561-568
54. Perico, N. and Remuzzi, G. (1998) Angiotensin II receptor antagonists and treatment of hypertension and renal disease. Curr. Opin. Nephrol. Hypertens. 7, 571-578
55. Giunti, S., Tesch, G.H., Pinach, S., Burt, D.J., Cooper, M.E., Cavallo-Perin, P., Camussi, G. and Gruden, G. (2008) Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 51, 198-207
56. Kato, S., Luyckx, V.A., Ots, M., Lee, K.W., Ziai, F., Troy, J.L., Brenner, B,M. and Mackenzie, H.S. (1999) Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int. 56, 1037-1048
57. Ziyadeh, F.N., Hoffman, B.B., Han, D.C., Iglesias-De La Cruz, M.C., Hong, S.W., Isono, M., Chen, S., McGowan, T.A. and Sharma, K. (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 97, 8015-8020
58. Chow, F.Y., Nikolic-Paterson, D.J., Ozols, E., Atkins, R.C., Rollin, B.J. and Tesch, G.H. (2006) Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 69, 73-80
59. Ferrara, N., Gerber, H.P. and LeCouter, J. (2003) The biology of VEGF and its receptors. Nat. Med. 9, 669-676
60. De Vriese, A.S., Tilton, R.G., Elger, M., Stephan, C.C., Kriz, W. and Lameire, N.H. (2001) Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J. Am. Soc. Nephrol. 12, 993-1000
61. Sung, S.H., Ziyadeh, F.N., Wang, A., Pyagay, P.E., Kanwar, Y.S. and Chen, S. (2006) Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J. Am. Soc. Nephrol. 17, 3093-3104
62. Rizkalla, B., Forbes, J.M., Cao, Z., Boner, G. and Cooper, M.E. (2005) Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system. J. Hypertens. 23, 153-164
63. Ichinose, K., Maeshima, Y., Yamamoto, Y., Kinomura, M., Hirokoshi, K., Kitayama, H., Takazawa, Y., Sugiyama, H., Yamasaki, Y., Agata, N. and Makino, H. (2006) 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes 55, 1232-1242
64. Lim, H.S., Lip, G.Y. and Blann, A.D. (2005) Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 180, 113-118
65. Yao, D., Taguchi, T., Matsumura, T., Pestell, R., Edelstein, D., Giardino, I., Suske, G., Rabbani, N., Thornalley, P.J., Sarthy, V.P. et al. (2007) High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J. Biol. Chem. 282, 31038-31045
66. Chang, H., Wang, B.W., Kuan, P. and Shyu, K.G. (2003) Cyclical mechanical stretch enhances angiopoietin-2 and Tie2 receptor expression in cultured human umbilical vein endothelial cells. Clin. Sci. 104, 421-428
67. Davis, B., Dei, C.A., Long, D.A., White, K.E., Hayward, A., Ku, C.H., Woolf, A.S., Bilous, R., Viberti, G. and Gnudi, L. (2007) Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J. Am. Soc. Nephrol. 18, 2320-2329
68. Gaede, P., Vedel, P., Larsen, N., Jensen, G.V., Parving, H.H. and Pedersen, O. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348, 383-393